Last edition
News about "Lupin receives US FDA approval for loteprednol eta"
Lupin receives US FDA approval for loteprednol etabonate ophthalmic gel
Loteprednol etabonate ophthalmic gel, 0.38% is bioequivalent to Lotemax SM ophthalmic gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin’s Pithampur facility in India.<br />
Lupin Receives US FDA Approval For Loteprednol Eta | 02/07/2025 | By Darshana | 231
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members